Fig. 6.

A2AR-CB1R heteromer-mediated control of the evoked glutamate release from striatal nerve terminals. a Concentration-response curves of the inhibitory effect of WIN55,2121-2 (WIN) on the evoked glutamate release, expressed as the difference in % of the control value, alone or in the presence the A2AR agonist CGS21680 (CGS, 0.03 μM), the A2AR antagonist SCH58261 (SCH, 0.1 μM), or both. Data are means ± S.E.M. of 7–14 experiments with duplicates per treatment and concentration. b–d Individual results from the experiments shown in a with WIN at the concentrations of 0.01 μM (b), 0.03 μM (c), and 0.1 μM (d), administered alone or in the presence of CGS (0.03 μM), SCH (0.1 μM), or both (yellow dots). e Effect of the peptides TM5 and TM7 of the A2AR on the inhibitory effect of WIN (0.03 μM) on the evoked glutamate release, expressed as the difference in % of the control value, alone or in the presence of CGS (0.03 μM) or SCH (0.1 μM). f Effect of CGS (0.03 μM), SCH (0.1 and 10 μM), or SCH (10 μM) plus WIN (0.3 μM). b–f Values are means ± S.E.M. (n = 7–14 with duplicates) of the evoked glutamate release, expressed as the difference in % of the control value, and analyzed statistically with one-sample t-test (*: p < 0.05/3; see “Methods”)